Correlation Between Design Therapeutics and Crinetics Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Design Therapeutics and Crinetics Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Design Therapeutics and Crinetics Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Design Therapeutics and Crinetics Pharmaceuticals, you can compare the effects of market volatilities on Design Therapeutics and Crinetics Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Design Therapeutics with a short position of Crinetics Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Design Therapeutics and Crinetics Pharmaceuticals.

Diversification Opportunities for Design Therapeutics and Crinetics Pharmaceuticals

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Design and Crinetics is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Design Therapeutics and Crinetics Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crinetics Pharmaceuticals and Design Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Design Therapeutics are associated (or correlated) with Crinetics Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crinetics Pharmaceuticals has no effect on the direction of Design Therapeutics i.e., Design Therapeutics and Crinetics Pharmaceuticals go up and down completely randomly.

Pair Corralation between Design Therapeutics and Crinetics Pharmaceuticals

Given the investment horizon of 90 days Design Therapeutics is expected to generate 2.77 times more return on investment than Crinetics Pharmaceuticals. However, Design Therapeutics is 2.77 times more volatile than Crinetics Pharmaceuticals. It trades about 0.13 of its potential returns per unit of risk. Crinetics Pharmaceuticals is currently generating about 0.06 per unit of risk. If you would invest  524.00  in Design Therapeutics on September 1, 2024 and sell it today you would earn a total of  76.00  from holding Design Therapeutics or generate 14.5% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Design Therapeutics  vs.  Crinetics Pharmaceuticals

 Performance 
       Timeline  
Design Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Crinetics Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Design Therapeutics and Crinetics Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Design Therapeutics and Crinetics Pharmaceuticals

The main advantage of trading using opposite Design Therapeutics and Crinetics Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Design Therapeutics position performs unexpectedly, Crinetics Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crinetics Pharmaceuticals will offset losses from the drop in Crinetics Pharmaceuticals' long position.
The idea behind Design Therapeutics and Crinetics Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bonds Directory
Find actively traded corporate debentures issued by US companies